Catalog No.
Product Name
Application
Product Information
Citations
-
DNA Topoisomerase II Inhibitor
Topoisomerase IIα-IN-4 is a non-intercalative ATP-competitive inhibitor targeting human DNA topoisomerase II. With an IC50 of 3.8 μM for TopoIIα and 10.1 μM for TopoIIβ, it effectively induces apoptosis and causes cell cycle arrest in HepG2 cells. Its potent antitumor activity against various human cancer cell lines makes Topoisomerase IIα-IN-4 a valuable reagent for cancer research and therapeutic studies. -
CDK2/Topo I Inhibitor
ZLHQ-5f is a dual inhibitor of Cyclin-dependent kinase 2 (CDK2) and Topoisomerase I (Topo I), exhibiting an IC50 of 0.145 μM against CDK2/CycA2. This compound effectively induces S-phase cell cycle arrest and triggers apoptosis in HCT116 cancer cells. Its favorable safety profile supports its potential applications in cancer research and therapeutic development. -
TopoisomeraseI/II Inhibitor
Erythro-Austrobailignan-6 is a selective inhibitor of DNA topoisomerase I and II, exhibiting anti-cancer properties. This compound induces apoptosis in cancer cells while also promoting the phosphorylation of p38 and JNK signaling pathways. Its ability to interfere with DNA replication makes it a valuable tool for research in cancer biology and therapeutic development. -
Top/HDAC Dual Inhibitor
Top/HDAC-IN-2 is a dual inhibitor targeting topoisomerase and histone deacetylases (HDACs). This compound demonstrates significant antitumor activity and effectively induces apoptosis in cancer cells. Its ability to concurrently interfere with these critical pathways makes it a valuable tool for researchers investigating cancer therapeutics and cell death mechanisms. -
Topo II/ HDAC Inhibitor
Topo II/HDAC-IN-2 is a potent dual inhibitor targeting topoisomerase II (Topo II) and histone deacetylases (HDAC). This compound is known to induce apoptosis in various cancer cell lines, making it a valuable tool for investigating the mechanisms of tumorigenesis and potential therapeutic interventions. Research applications include studies on cancer biology, drug development, and the modulation of epigenetic regulators. -
DNA Topoisomerase II Inhibitor
DNA Topoisomerase II Inhibitor 1 is a potent inhibitor of DNA topoisomerase II, a crucial enzyme involved in DNA replication and maintenance. This compound exhibits significant anti-proliferative activity by inducing apoptosis and causing cell cycle arrest at the sub-G1 phase. It serves as a valuable tool for research in cancer biology and therapeutic studies targeting cell growth and survival pathways. -
HDAC Inhibitor, Topoisomerase I Inhibitor
WJ35435 is a dual-target HDAC and topoisomerase I inhibitor that exerts anticancer activity by inducing DNA damage and promoting cell cycle arrest at the G1 and G2 phases, ultimately leading to apoptosis. This compound enhances histone H3 acetylation and phosphorylation, along with α-tubulin acetylation and the formation of γ-H2AX, thereby effectively demonstrating its anti-HDAC properties. WJ35435 holds potential for advancing research in cancer therapeutics. -
Topoisomerase II Inhibitor
Topoisomerase II inhibitor 10 is a potent inhibitor of the topoisomerase II enzyme, exhibiting an IC50 value of 7.45 µM. This compound effectively induces cell cycle arrest in the G2-M phase and promotes apoptosis in HepG-2 cells. Additionally, Topoisomerase II inhibitor 10 demonstrates significant anti-proliferative activity against various cancer cell lines, including HepG-2, MCF-7, and HCT-116, making it a valuable tool for cancer research applications. -
DNA Gyrase/Topoisomerase Inhibitor
Levofloxacin sodium is a potent DNA gyrase and topoisomerase IV inhibitor that exhibits broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria. Its primary applications include research on chronic periodontitis, airway inflammation, and BK viremia. Additionally, Levofloxacin sodium demonstrates anti-orthopoxvirus properties, making it a valuable reagent for studies involving viral infections. -
Topoisomerase I Inhibitor.
T-2513 hydrochloride is a selective inhibitor of topoisomerase I. By covalently binding to and stabilizing the topoisomerase I-DNA complex, it effectively inhibits DNA replication and RNA synthesis, resulting in cytotoxicity. This compound is utilized in research applications focused on cancer biology and the mechanisms of chemotherapeutic agents. -
Topoisomerase II Inhibitor
NK-611 is a topoisomerase II inhibitor that functions as an epipodophyllotoxin derivative. By inhibiting topoisomerase II with an IC50 of 56 μM, NK-611 induces DNA double-strand breaks, leading to effective antitumor activity. Unlike its parent compound Podofilox, NK-611 does not interfere with microtubule polymerization, thus minimizing associated side effects. This compound has shown potent efficacy in in vivo leukemia models and is valuable for cancer research applications. -
Topoisomerase I Inhibitor
T-2513 is a selective inhibitor of topoisomerase I, a critical enzyme involved in the relaxation of DNA supercoils during replication and transcription. By covalently binding to and stabilizing the topoisomerase I-DNA complex, T-2513 effectively inhibits DNA replication and RNA synthesis. This activity may induce cytotoxic effects, making it a valuable tool in cancer research and studies focused on cell proliferation and death. -
Topoisomerase II Inhibitor
F-14512 hydrochloride is a potent inhibitor of topoisomerase II, functioning through the polyamine transport system (PTS) to selectively target cancer cells. By enhancing the binding affinity of polyamines to DNA, it effectively inhibits topoisomerase II activity, leading to significant cytotoxic effects in cells with elevated PTS activity and resulting in DNA damage. Additionally, F-14512 hydrochloride exhibits strong antitumor efficacy in the MX1 breast tumor xenograft model, making it a valuable reagent for cancer research, particularly in studies focusing on breast cancer. -
DNA topoisomerase II Inhibitor
NSC 660028 is a potent inhibitor of DNA topoisomerase II, exhibiting an ID50 of 50 μM. This compound disrupts DNA topoisomerase II activity, leading to the induction of protein-linked DNA breaks. NSC 660028 is primarily utilized in cancer research to explore mechanisms of tumor cell proliferation and resistance. -
Topoisomerase II Inhibitor
KW-2170 hydrochloride is a potent topoisomerase II inhibitor that functions by stabilizing the topoisomerase II-DNA complex. This stabilization leads to DNA double-strand breaks, thereby inhibiting DNA replication and transcription, which ultimately results in tumor cell death. KW-2170 hydrochloride demonstrates broad-spectrum anti-tumor activity in various mouse and human tumor models, making it a valuable reagent for research related to solid tumors. -
Topoisomerase Inhibitor
NSC 727357 is a potent topoisomerase inhibitor and DNA intercalator, exhibiting significant antitumor activity. It effectively inhibits cell proliferation and induces G1 phase cell cycle arrest. This compound is particularly relevant for cancer research, including studies focused on melanoma. -
Topoisomerase Inhibitor
Netropsin is a small-molecule minor-groove binder that functions as a topoisomerase inhibitor. It effectively inhibits the catalytic activity of isolated topoisomerase, disrupting the stabilization of cleavable complexes associated with both topoisomerase I and II. Additionally, Netropsin exhibits antibacterial and antiviral properties, making it a valuable tool for research in the fields of microbiology and virology. -
Topoisomerase II/DNA Polymerase Inhibitor
Epolactaene is a potent inhibitor of Topoisomerase II and DNA Polymerases, exhibiting IC50 values of 10 µM for Topoisomerase II, 25 µM for DNA Polymerase α, and 94 µM for DNA Polymerase β. Its ability to interfere with these key enzymes makes Epolactaene valuable for studying DNA replication and repair mechanisms. This compound is suitable for research applications involving cancer biology and the investigation of DNA-targeting therapies. -
Topoisomerase I Inhibitor
Topoisomerase I inhibitor 11 is a potent inhibitor of Topoisomerase I, a key enzyme involved in DNA replication and repair. This compound disrupts the enzyme's catalytic activity, leading to the accumulation of DNA damage and ultimately inducing apoptosis in cancer cells. Topoisomerase I inhibitor 11 is primarily utilized in cancer research, particularly for studying mechanisms of drug resistance and the therapeutic potential of targeting Topoisomerase I in various malignancies. -
Fluoroquinolone antibiotic
ABT-492 is a new fluoroquinolone against 155 aerobic and 171 anaerobic pathogens. -
Topoisomerase inhibitor
Cerubidine (Daunorubicin HCl, Rubidomycin HCl) interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. It stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication.
-
Topoisomerase II inhibitor
Epirubicin is a cell-permeable anthracycline antitumor antibiotic. It is a stereoisomer(4?€?-epi-isomer) of doxorubicin that exhibits reduced cardiotoxicity. It is used to inhibit topoisomerase II and DNA helicase activity. -
DNA gyrase/topoisomerase IV inhibitor
Gatifloxacin is a fluoroquinolone antibiotic which inhibits bacterial DNA gyrase (IC50 = 0.109 ng/ml) and topoisomerase IV (IC50 = 13.8 ng/ml). - Levofloxacin is a fluoroquinolone antibiotic. It is active against S. aureus, S. epidermidis, B. subtilis, E. coli, P. aeruginosa, and K. pneumoniae (MICs = 0.25, 0.25, 0.5, 0.03, 4, and 0.25 μg/ml, respectively).
-
Topoisomerase inhibitor
Marbofloxacin is a potent antibiotic of the 3rd generation fluoroquinolone group and acts by inhibiting bacterial DNA replication. - Mitoxantrone Dihydrochloride is an antiviral, antibacterial, antiprotozoal, immunomodulating, and antineoplastic cytostatic anthraquinone derivative.
-
Topoisomerase inhibitor
Norfloxacin(Norxacin) is a broad-spectrum antibiotic. -
Topoisomerase inhibitor
Ofloxacin is a synthetic broad-spectrum antimicrobial agent. - Podophyllotoxin is a potent inhibitor of microtubule assembly that binds at the colchicine site of tubulin.
- Teniposide is a semisynthetic derivative of podophyllotoxin with antineoplastic activity.
-
DNA topoisomerase I inhibitor
Topotecan HCl (Hycamtin) is a chemotherapeutic agent that is a topoisomerase inhibitor. -
ADCs cytotoxin
PNU-159682, a highly potent metabolite of the anthracycline nemorubicin (DNA topoisomerase II inhibitor) with outstanding cytotoxicity, is a potent ADCs cytotoxin. -
DNA gyrase/topoisomerase inhibitor
Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor. -
Topoisomerase agonist
Groenlandicine is a protoberberine alkaloid isolated from Coptidis Rhizoma. Groenlandicine exhibits moderate inhibitory effect with IC50 value of 154.2 μM for human recombinant aldose reductase (HRAR). -
Alkaloid
Berberine (Natural Yellow 18) is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine (Natural Yellow 18) induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Berberine (Natural Yellow 18) has antineoplastic properties.
-
Topoisomerase IV Inhibitor
Ciprofloxacin is a potent topoisomerase IV inhibitor that demonstrates significant antibacterial activity as a fluoroquinolone antibiotic. It induces both mitochondrial and nuclear DNA damage, leading to mitochondrial dysfunction and increased reactive oxygen species (ROS) production. Ciprofloxacin exhibits anti-proliferative properties and triggers apoptotic pathways, making it a valuable tool for research applications focused on bacterial infections, oxidative stress, and cancer biology. -
Topoisomerase I Inhibitor
Irinotecan hydrochloride is a potent inhibitor of topoisomerase I, an enzyme crucial for DNA replication and transcription. This compound exhibits significant anti-tumor activity, primarily in the treatment of colorectal cancers. Its mechanism involves the stabilization of the enzyme-DNA complex, leading to apoptosis in cancer cells. Irinotecan hydrochloride is widely utilized in cancer research to elucidate cellular response mechanisms and to develop novel therapeutic strategies. -
Topoisomerase IIα Inhibitor
Topoisomerase II-IN-24 is a selective inhibitor of Topoisomerase IIα, exhibiting an IC50 of 41.67 μM. This compound has been shown to effectively inhibit the proliferation of cancer cells while inducing G2/M phase arrest and promoting apoptosis. Topoisomerase II-IN-24 is valuable for research focusing on cancer biology, particularly in the study of colon cancer. -
Topoisomerase I/II Inhibitor
Topoisomerase I/II Inhibitor 8 is a dual-target inhibitor that effectively disrupts the function of both Topoisomerase I and II, leading to DNA damage. This compound activates PARP-1, which in turn stimulates the necroptotic pathway via RIPK1, RIPK3, and MLKL signaling. Exhibiting significant anticancer properties, Topoisomerase I/II Inhibitor 8 induces cell death in cancer cells, presenting a promising approach to overcome drug resistance in cancer therapies. -
Topoisomerase I Inhibitor
Topoisomerase I Inhibitor 2 targets DNA topoisomerase I (Top1) with high specificity, effectively inhibiting its activity and leading to DNA damage. This compound not only induces apoptosis but also disrupts the G2/M phase of the cell cycle, thereby exhibiting significant anti-tumor effects. Its properties make it a valuable tool for cancer research and therapeutic studies focused on DNA damage response mechanisms. -
Topoisomerases Inhibitor
Pyrazoloacridine is a potent inhibitor of topoisomerases 1 and 2, functioning as an intercalating agent with notable anti-cancer activity. This compound demonstrates cytotoxicity in K562 myeloid leukemia cells, exhibiting an IC50 of 1.25 μM following a 24-hour treatment. Pyrazoloacridine is primarily utilized in cancer research to explore mechanisms of tumor cell proliferation and resistance. -
Topoisomerase II Inhibitor
Etoposide phosphate disodium is a selective inhibitor of topoisomerase II, acting as a potent anti-cancer agent. This phosphate ester prodrug of etoposide effectively prevents the re-ligation of DNA strands, leading to cell cycle arrest, apoptosis, and autophagy in cancer cells. It is utilized in cancer research for its ability to induce programmed cell death and its therapeutic implications in chemotherapy. -
Topoisomerase II Inhibitor
Daunorubicin citrate is a potent inhibitor of topoisomerase II, exerting significant anti-tumor activity. This cytotoxic agent interferes with DNA and RNA synthesis, leading to reduced cancer cell viability and the induction of apoptosis and necrosis. As an anthracycline antibiotic, daunorubicin citrate is utilized in research related to various cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, and Wilms' tumor, as well as studies on infectious diseases. -
Topoisomerase II Inhibitor
Topoisomerase II inhibitor 11 is a potent inhibitor of topoisomerase II, exhibiting an IC50 of 2.89 μM. It demonstrates significant antiproliferative activity, achieving 92.46% inhibition in the renal cancer cell line A498 with an IC50 of 3.5 μM. This compound induces cell cycle arrest at the G2/M phase, ultimately leading to inhibited cell proliferation and pro-apoptotic effects, making it an important tool for cancer research. -
Topoisomerase Inhibitor
Cholesteryl hemisuccinate is a topoisomerase inhibitor with notable hepatoprotective and anticancer properties. It effectively mitigates acetaminophen-induced hepatotoxicity by preventing hepatic apoptosis and necrosis. Additionally, cholesteryl hemisuccinate interferes with DNA replication and repair mechanisms by inhibiting DNA polymerase and DNA topoisomerase, ultimately leading to reduced tumor growth. This compound is suitable for applications in cancer research and liver protection studies. -
Topoisomerase II Inhibitor
Etoposide phosphate is a selective inhibitor of topoisomerase II, instrumental in disrupting DNA re-ligation processes. As the phosphate ester proagent of etoposide, it exhibits potent anti-cancer activity by inducing cell cycle arrest, apoptosis, and autophagy in cancer cells. This compound is primarily employed in cancer research to explore mechanisms of action and potential therapeutic strategies in oncology. -
Topoisomerase II Inhibitor
ICRF-193 is a potent inhibitor of DNA Topoisomerase II, disrupting DNA synthesis and inducing apoptosis in cancer cells. This compound exhibits significant anti-cancer and anti-inflammatory activities, making it valuable for research in oncology and inflammation. Additionally, ICRF-193 demonstrates cardioprotective properties against anthracycline-induced toxicity in cardiomyocytes. It is particularly relevant for studies focusing on acute promyelocytic leukemia, as well as broader investigations into cancer, infection, inflammation, and cardiovascular conditions.
